Abstract: A drug and device combination system used in a method for treatment of patients suffering from severe and oral corticosteroid-dependent asthma and other respiratory diseases requiring a treatment with orally administered steroids. The method for administration of the inhalable corticosteroid by a flow rate and volume regulated inhalation. The combination system of the inhalable corticosteroid and the device for regulating flow rate and volume of the inhalable corticosteroid and thus achieving delivery of said inhalable corticosteroid into the small airways of the lungs. The individually programmable device that assures safe and reproducible corticosteroid delivery compliant with treatment protocol.

Abstract: Methods, devices and compositions for treatment of severe and uncontrolled asthma are provided by which high amounts of an inhaled corticosteroid are directed to the small airways of the lower lungs. The invention provides for a substantial decrease in the dose of concurrently administered oral corticosteroids. A particular advantage of the invention is the significant reduction in corticosteroid-related adverse effects.

Abstract: Materials with high levels of unsaponifiable matter, such as extracts from plants, produce hydrolysates with unique properties. Properties that are sought in traditional saponification of natural oils are a result of low levels of unsaponifiables. These properties include high levels of aqueous surfactant activity, water-solubility or ready water-dispersability, activity as foaming agents, and the like. An objective of traditional saponification processes is to increase the water-solubility and surfactant activity of naturally occurring materials. It has been found that the application of a hydrolysis process to materials, particularly materials with a high level of unsaponifiables (e.g., at least 6 weight percent of the material), produces a product with properties significantly different from those products resulting from the conventional saponification of materials with less than 6 weight percent of unsaponifiables.

Abstract: The present invention relates to odour improved dermatological or cosmetic preparations comprising N-acetylcysteine and a polyol system containing one or more polyols as masking odour agents. The emulsions of the present invention are useful in the treatment of dermatological disorders or cosmetic skin conditions.

Abstract: Disclosed are formulae and methods for the simultaneous relief of a variety of unpleasant symptoms of poison ivy on the skin. The compositions of the present invention remove toxic urushiol, relieve itching of the skin from urushiol, and heal the dermatitis caused by urushiol. A preferred embodiment of the invention is a topical dosage form which can be applied as often as desired, may be scrubbed onto the skin, and leaves a soothing effect on the skin after rinsing with warm water.

Abstract: This invention relates to a method for the natural topical treatment of portions of skin of a person afflicted with a skin disorder such as dry skin, eczema, itchy skin, red skin, itchy eczema, inflamed skin, and/or cracked skin for the removal of itch and the restoration of the affected areas of skin to a normal condition. The natural treatment of a skin disorder initially involves formation of a natural ointment from the ingredients identified as lard; Marigold flowers; and pure beeswax. The natural ointment is formed by combination of the ingredients which includes heating. The ointment is then applied twice daily to affected areas of skin until a natural cure of the skin disorder is obtained. In addition, a therapeutic compress is applied to the affected skin. The compress may include Colts Foot Leaf, White Oak Bark, Burdock Root, Horsetail Herb, and water.

Abstract: A solution for urushiol induced contact dermatitis is provided for in a topical solution. According to the invention, a method is provided for applying a composition of substances to the affected area, working the composition into the affected area, and removing the composition from the affected area. The composition comprises at least one ethoxylate in combination with a supporting agent. It is believed that this combination binds to the available urushiol receptors rendering it inactive. The affinity of the receptors for the ethoxylates also appears to cause a release of the urushiol from its epidermal bonds for bonding to the composition. An inert scrubbing agent, such as polyethylene beads, can also be included to assist in the release of the urushiol. Acetylated lanolin alcohol, EDTA, a foam stabilizer, and water can also be added to the composition without effecting performance.

Abstract: The invention relates to the use of one or more antimicrobial metals, most preferably silver, preferably formed with atomic disorder, and preferably in a nanocrystalline form, for the treatment of inflammatory skin conditions. The nanocrystalline antimicrobial metal of choice may be used in the form of a nanocrystalline coating of one or more antimicrobial metals, a nanocrystalline powder of one or more antimicrobial metals, or a solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial metals.

Abstract: The invention discloses the discovery that a pharmaceutical composition containing complex carbohydrates and natural or synthetic essential oils can work effectively as a topical pharmaceutical composition. Such pharmaceutical compositions reduce inflammation, assist in wound healing, protect against bruising, relieve itching, relieve pain and swelling and treat topical bacterial infections such as acne and decubitus ulcers. Such pharmaceutical compositions can be administered to mammals including humans. Also included in this invention are methods to deliver topically applied macromolecules into the tissue of mammals and methods of blocking the adhesion cascade.

Abstract: Composition for topical administration comprising (a) a corticosteroid, and (b) a drying agent.

Abstract: Compositions are provided for the topical treatment of cancer consisting of lotions, creams, sprays, suppositories or slow-release transdermal patches containing lipid-soluble, skin-penetrating organic selenium compounds in combination with inert carriers in therapeutically effective amounts of selenium compound. The selenium compounds are medium linear chain dialkyl diselenides and precursors such as alkyl selenols. Preferred compositions employ R—Se—Se—R compounds where R is from 6 to 8 carbon atoms, and most specifically di-n-hexyl diselenide. Commonly used carriers may be purified hydrocarbon fractions, oils, with or without added fat-soluble vitamins, water and emulsifying agents.

Abstract: Methods and pharmaceutical compositions employing (+) cetirizine, (−) cetirizine, or racemic cetirizine, or a pharmaceutically acceptable salt thereof, and a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, or decongestant for the treatment, management, and/or prevention of inflammation, asthma or symptoms thereof, allergic disorders such as allergic rhinitis, and dermatitis.

Abstract: Compositions and methods for treating wounds to significantly reduce the healing time, reduce the incidence of scar formation, improve the success of skin grafts, reduce the inflammatory response and providing anti-bacterial treatments to a patient in need thereof, that include small non-interlinked particles of bioactive glass or highly porous bioactive glass, are disclosed. Anti-bacterial solutions derived from bioactive glass, and methods of preparation and use thereof, are also disclosed. The compositions include non-interlinked particles of bioactive glass, alone or in combination with anti-bacterial agents and/or anti-inflammatory agents. The compositions can include an appropriate carrier for topical administration. Anti-bacterial properties can be imparted to implanted materials, such as prosthetic implants, sutures, stents, screws, plates, tubes, and the like, by incorporating small bioactive glass particles or porous bioactive glass into or onto the implanted materials.

Abstract: The invention relates to a polyoxometalate topical composition for removing a contaminant from an environment, comprising a topical carrier and at least one polyoxometalate, with the proviso that the polyoxometalate is not H5PV2Mo10O40; K5Si(H2O)MnIIIW11O39; K4Si(H2O)MnIVW11O39; or K5CoIIIW12O40. The invention further relates to a method for removing a contaminant from an environment, comprising contacting the polyoxometalate topical composition of the present invention with the environment containing the contaminant for a sufficient time to remove the contaminant from the environment. The invention further relates to a modified polyoxometalate, wherein the modified polyoxometalate comprises the admixture of (1) a polyoxometalate and (2) a cerium compound, a silver compound, a gold compound, a platinum compound, or a combination thereof.

Abstract: A gel formulation is combined with a bactericidal concentrate which is a liquid mixture of about 1000 parts by volume of ultra pure water having an electrical resistance of 16-26 megohms, total dissolved solids of less than 0.04 parts per million and a specific conductance of less than 0.10 mho with about 1.2 to 3 parts by volume of Willard Water as prepared in accordance with U.S. Pat. No. 3,893,943. The bactericidal liquid concentrate in the amount of 3.5 to 12 ml in one liter of gel formulation is applied directly to a skin surface area having a burn or other dermal lesion to protect the area from bacterial contamination.

Abstract: A topical composition is disclosed for reducing a urushiol-induced allergic response and the dermatitis associated therewith. The composition is a preparation having an acorn derivative and a nontoxic dermatologically acceptable aqueous dispersion material. The acorn derivative is acorn ash, acorn mash, roasted acorn, or acorn extract and comprises about 0.1 to 50 percent by weight of the treating preparation. After the initial preparation, preservatives are then added. Optionally, additional ingredients such as surfactants and emulsifying agents, antihistamines, topical anesthetics, colloidal oatmeal, topical antipruritics, astringents, and emollients may be added to the aqueous acorn dispersion. With processing varied according the examples provided, the ingredients are combined so as to create sprays, creams, gels, ointments, and lotions.

Abstract: A composition for use by animals, including humans, to alleviate pain and/or inflammation around a painful joint, joint replacement surgery site, muscle, tendon, and/or ligament. A method to ameliorate pain and/or inflammation in or around a joint, muscle, tendon, and/or ligament, by topically applying Applicant's composition.

Abstract: The invention concerns a method for preparing aloin which consists in extracting from a substance containing aloe, in particular the yellow sap of aloe or a derived product, in the presence of an aliphatic diol or triol with low molecular weight, for instance glycerol or a glycol, followed by a purification by crystallization in an alcohol. The invention is useful for industrial preparation of aloin.

Abstract: Composition for topical administration comprising (a) a corticosteroid, and (b) a drying agent.

Abstract: The present invention provides a therapeutic agent for dermatitis, particularly a therapeutic agent for atopic dermatitis, which is very safe and which shows few adverse side-effects in comparison to, for example, steroidal agents. The present invention relates to a therapeutic agent containing a compound represented by the following formula (I) or a pharmaceutically acceptable salt or hydrate thereof as an effective ingredient: wherein R is hydrogen or a halogen. The therapeutic agent for dermatitis according to the present invention effectively and in a dose-dependent manner suppresses antigen-induced swelling in a mouse ear, a recognized animal model for atopic dermatitis, and suppresses the antigen-induced flare-up reaction in mice which occurred with the swelling reaction. In addition, no adverse reaction in the skin are observed.

Abstract: A treatment for urushiol induced contact dermatitis is provided for in a topical treatment. According to the invention, a method is provided for applying a composition of substances to the effected area, working the composition into the effected area, and removing the composition from the effected area. The composition comprises at least one ethoxylate in combination with Sodium Lauryl Sarcosininate (or “SLS”). It is believed that this combination binds to the available urushiol receptors rendering it inactive. The affinity of the receptors for the ethoxylates also appears to cause a release of the urushiol from its epidermal bonds for bonding to the composition. An inert scrubbing agent, such as polyethylene beads, can also be included to assist in the release of the urushiol. Acetylated lanolin alcohol, sodium lauroyl sarconinate, EDTA, a foam stabilizer, and water can also be added to the composition without effecting performance.

Abstract: This invention relates to a method for treating inflammatory symptoms such as burning, redness, itching, swelling and pain which accompany skin disorders other than wounds of the skin. The method comprising topical application of a topical medicinal composition comprising a non-interlinked, particulate bioactive glass mixed with a topical medicinal carrier to the site of the skin disorder.

Abstract: The concentrate is a liquid mixture of about 1000 parts by volume of ultra pure water having an electrical resistance of 16-26 megohms, total dissolved solids of less than 0.04 parts per million and a specific conductance of less than 0.10 microhmo to about 1.2 to 3 parts by volume of Willard Water as prepared in accordance with U.S. Pat. No. 3,893,943. The liquid concentrate is applied directly to a skin surface area having a burn or other dermal lesion to protect the area from bacterial contamination.

Abstract: The present invention is directed to methods and compositions for treating skin disorders. The present invention is easily administered and can be used for both humans and animals. The compositions of the present invention comprise borate compounds and provide relief from skin disorder symptoms and lesions. Additionally, the present invention can be used to provide long term maintenance of symptom-free skin.

Abstract: It has been found that certain antihistamines can mediate the delayed dermatitis and in particular that caused by poison ivy and poison sumac or poison oak. Especially useful are antihistamines having a high degree of intrinsic activity as shown by their low oral dosage as antihistamine (0.1-10, suitably 1-2 mg), which can be topically administered at a sufficiently high active concentration to be effective in the treatment of allergic reactions. Compositions and methods of utilizing such compositions for these purposes are disclosed.

Abstract: Methods and pharmaceutical compositions employing (+) cetirizine, (−) cetirizine, or racemic cetirizine, or a pharmaceutically acceptable salt thereof, and a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, or decongestant for the treatment, management, and/or prevention of inflammation, asthma or symptoms thereof, allergic disorders such as allergic rhinitis, and dermatitis.

Abstract: A method of treatment for a mammal in need of analgesia from an itching skin comprising applying by directional friction against the skin proximate to the itch a composition consisting essentially of dry elemental iodine in the form of an amorphous condensate. The method is found effective in producing analgesia to the affected skin within 1 to 5 minutes after application.

Abstract: Compositions for inhibiting nematocyst or polar capsule discharge are provided in the form of an effective amount of antihistamine, an effective amount of antihistamine and an effective amount of at least one cation, or an effective amount of at least one cation. The compositions can be in the form of ointments or can be added to the environment surrounding the nematocysts or polar capsules. Methods of inhibiting nematocyst or polar capsule discharge using the compositions of the invention are also provided.

Abstract: A therapeutic composition having plantain and aloe vera constituents is useful in the treatment of the symptoms of arthritis and other afflictions. The therapeutic composition may have only plantain and aloe vera constituents, wherein the plantain constituent is in a range of approximately 57% to 61% by weight of the therapeutic composition and the aloe vera constituent is in a range of approximately 39% to 43% by weight of the therapeutic composition. The therapeutic composition may have other constituents, such as herbal tinctures, added for various purposes, in which case, the plantain constituent is in a range of approximately 51% to 58% by weight of the therapeutic composition, the aloe vera constituent is in a range of approximately 37% to 39% by weight of the therapeutic composition, and the other constituent is in the range of approximately 5% to 10% by weight of the therapeutic composition.

Abstract: A botanical composition for soothing irritated skin and method of producing the composition. The composition includes 90-97% by weight aloe juice; 1-5% by weight grapefruit seed and pulp extract; and 1-5% by weight vegetable glycerine. The aloe juice, grapefruit seed and pulp extract and vegetable glycerine are mixed together to form a liquid mixture for application to and covering the irritated skin. The grapefruit seed and pulp extract preferably has a pH of 3. A fragrance may be added to the composition to provide a desired odor to the composition and oils may be added to the composition for use in hydrating the irritated skin on which the composition is applied. The composition is stored in a spray bottle for creating a mist of the composition when applying the composition to the irritated skin.

Abstract: The present invention relates to cosmetic or dermatological compositions capable of being applied to the skin, the keratinous fibers, the nails, the semimucous membranes and/or the mucous membranes, and which includes a dendritic polyester polymer having terminal hydroxyl functional groups or the combination of such a polymer with a film-forming polymer. It also relates to methods of cosmetic or dermatological treatment using these compositions as well as the use of the compositions for the preparation of dermatological or cosmetic compositions.

Abstract: The present invention relates to an antiwrinkle composition that includes, in a physiologically acceptable medium: a dispersion of a film-forming polymeric system containing at least one polymer capable of forming a film permeable to water vapor, having a Young's modulus ranging from 108 to 1010 N/m2 and producing, after application at a concentration of 7% in water and then drying, a retraction of the isolated stratum corneum greater than 1% at a temperature of 30° C. and a relative humidity of 40%, and a dendritic polyester polymer having terminal hydroxyl functional groups.

Abstract: The present invention relates to use of dichlorobenzyl alcohol for preparing a preparation for topical treatment of inflammation and the preparation for this purpose. It is known to use dichlorobenzyl alcohol (2,4-DCBA) as an agent against bacteria and fungi, i.e. as a disinfectant. By the present invention it has, however, surprisingly turned out that dichlorobenzyl alcohol, preferably 2,4-dichlorobenzyl alcohol, is also useful for treatment of inflammation. The invention also relates to a preparation containing dichlorobenzyl alcohol, preferably 2,4-dichlorobenzyl alcohol, for topical treatment of inflammation, which can be applied onto skin or mucosa in the form of an ointment, a cream, a gel or a solution. Thus, the preparation has turned out to be effective against a variety of inflammatory conditions including skin diseases, such as pruritus and psoriasis, insect bites and stings.

Abstract: An antiallergic agent which is characterized in containing at least one compound selected from a group consisting of 4,5-dihydroxy-2-cyclopenten-1-one represented by the following formula [I] and an optically active substance and a salt thereof as an effective component.

Abstract: A method of treating skin disorders using a extract from the plant Mullein (genus Verbascum) and a composition including an extract from the plant Mullein (genus Verbascum) are described. The extract is obtained by cooking the leaves and roots of the plant Mullein in a pressure cooker with water. The resulting liquid extract is canned according to standard home canning procedures. The method is accomplished by applying the liquid extract to affected areas of the skin twice daily. Most subjects experience positive results within a period of approximately two weeks. Skin disorders that have been treated using this extract include the sun exposure related skin disorders, actinic keratoses, lentigines, seborrheic keratoses, and the inflammatory skin disorders including prurigo, psoriasis, and contact dermatitis. The skin cancer, malignant melanoma, has also been treated using this method.

Abstract: Compositions for inhibiting nematocyst or polar capsule discharge are provided in the form of an effective amount of antihistamine or an effective amount of antihistamine and an effective amount of at least one cation. The compositions can be in the form of ointments or can be added to the environment surrounding the nematocysts or polar capsules. Methods of inhibiting nematocyst or polar capsule discharge using the compositions of the invention are also provided.

Abstract: Plant resin exuded by poison ivy, poison oak, poison sumac and other plant resins are removed from the skin by successive applications of an alkaline cleanser and acidic stripper. The skin is first thoroughly washed with the alkaline cleanser. After rinsing the cleanser from the skin, the skin is daubed with the acidic stripper. The alkaline cleanser is a mixture of water, soap, turpentine, a mild abrasive, and mineral spirits. The acidic stripper is a mixture of an acid, and astringents such as tannin and witch hazel extract.

Abstract: The present invention relates to a composition, and a method for preventing or reducing contact dermatitis. The composition contains a polysaccharide; a low molecular weight, synergistic saccharide; a solvent; and optionally an additive material.The present invention is further a dermatologically-compatible barrier film for preventing and reducing contact dermatitis which contains a polysaccharide; a low molecular weight, synergistic saccharide; and optionally one or more additives. The dermatologically-compatible barrier film is formed of a composition containing a polysaccharide; a low molecular weight, synergistic saccharide; a solvent; and optionally an additive material. The composition is a skin care product in a form of a lotion, a gel or a cream that is applied to skin of mammals.

Abstract: The present invention includes a process and composition for treating skin disorders. The composition of the present invention comprises 94.0 to 99.2 percent by weight of cation-free water, 0.1 to 1.0 percent by weight of Calcium chloride, 0.0 to 2.0 percent by weight of linear long chain polyphosphate, 0.1 to 1.0 percent by weight of sodium bicarbonate and 0.5 to 3.0 percent by weight of cross-linked polyacrylamide polymer.

Abstract: The present invention is directed towards a method, a composition and an article of manufacture for protecting the skin from jellyfish stings. The method comprises topically contacting the skin with a composition containing polymeric quaternary ammonium salt in amounts sufficient to protect against the rupture of jellyfish nematocysts. The composition can be in the form of an emulsion, liquid dispersion, solution, skin cream, face cream, lotion or ointment.

Abstract: The present invention relates to a composition, and a method for preventing or reducing contact dermatitis. The composition contains a polysaccharide; a low molecular weight, synergistic saccharide; a solvent; and optionally an additive material.The present invention is further a dermatologically-compatible barrier film for preventing and reducing contact dermatitis which contains a polysaccharide; a low molecular weight, synergistic saccharide; and optionally one or more additives. The dermatologically-compatible barrier film is formed of a composition containing a polysaccharide; a low molecular weight, synergistic saccharide; a solvent; and optionally an additive material. The composition is a skin care product in a form of a lotion, a gel or a cream that is applied to skin of mammals.

Abstract: Compositions and processes for the prophylaxis and therapeutic treatment of wounds, chronic non-healing wounds, burns, disease and other dermal disorders are disclosed. The compositions of the present invention comprise aqueous solutions of a metal chlorite having a concentration of from about 0.002% to about 0.5% by weight of metal chlorite. The process of the present invention comprises treating the dermal disorder with an aqueous solution of from about 0.002% to about 0.5% by weight of a metal chlorite. Wounds, chronic non-healing wounds, burns and other dermal disorders treated in this manner heal more quickly and with reduced scar formation. The antiseptic compositions and processes of the present invention exhibit anticollagenous activity such that the characteristics of the healed skin, such as elasticity and tensile strength, are similar to undamaged skin.

Abstract: A composition containing capsaicin together with another ingredient to neutralize the discomfort resulting from the application of capsaicin to the skin can be used to treat many types of discomforts, including arthritis pain, hemorrhoid pain and itching, and poison ivy itching, without the discomfort normally associated with the topical application of capsaicin.

Abstract: The present invention relates to a composition, and a method for preventing or reducing contact dermatitis. The composition contains a polysaccharide; a low molecular weight, synergistic saccharide; a solvent; and optionally one or more additives. The present invention is further a dermatologically-compatible barrier film for preventing and reducing contact dermatitis which contains a polysaccharide; a low molecular weight, synergistic saccharide; and optionally one or more additives. The dermatologically-compatible barrier film is formed of a composition containing a polysaccharide; a low molecular weight, synergistic saccharide; a solvent; and optional additives. The composition is a skin care product in a form of a lotion, a gel or a cream that is applied to skin of mammals. Once applied, the solvent in the composition evaporates, and thereby leaving behind a dermatologically-compatible barrier film containing polysaccharide and low molecular weight, synergistic saccharide.

Abstract: The present invention relates to a composition, and a method for preventing or reducing contact dermatitis. The composition contains a polysaccharide; a low molecular weight, synergistic saccharide; a solvent; and optionally one or more additives.The present invention is further a dermatologically-compatible barrier film for preventing and reducing contact dermatitis which contains a polysaccharide; a low molecular weight, synergistic saccharide; and optionally one or more additives. The dermatologically-compatible barrier film is formed of a composition containing a polysaccharide; a low molecular weight, synergistic saccharide; a solvent; and optional additives. The composition is a skin care product in a form of a lotion, a gel or a cream that is applied to skin of mammals. Once applied, the solvent in the composition evaporates, and thereby leaving behind a dermatologically-compatible barrier film containing polysaccharide and low molecular weight, synergistic saccharide.

Abstract: An improved method for suppressing xenograft rejection in a host subject is disclosed. The method includes administering an immunosuppressant drug, where the drug or the amount of drug administered is, by itself, ineffective to suppress xenograft rejection. Effective xenograft suppression is achieved by also administering an ethanolic extract of Triterygium wilfordii or a purified triptolide component thereof.

Abstract: The invention provides a method for treating fungal dermatitis comprising administering an effective amount of 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno?2,3-b!?1,5!benzodiazepine to a patient in need thereof.

Abstract: A lotion capable of protecting the skin from the effects of exposure to irritants and allergens, particularly those produced by toxic plants such as poison ivy, has the following composition, wherein the proportions are by weight:______________________________________ organophilic clay 3.0-10.0% volatile alcoholic solvent 20.0-30.0% cosmetically acceptable inert 15.0-25.0% emollient vehicle thickener 2.0-10.0% water q.s.p. 100.

Abstract: A composition and method are described for the treatment of allergic contact dermatitis, such as poison ivy, poison oak, and poison sumac. The composition includes linseed oil, an astringent such as alum powder, a starch such as cornstarch, an essential oil such as eucalyptus oil, and a citrus oil such as orange oil. The method includes applying the treatment composition to an affected area of skin, preferably once to twice per day.

Abstract: Disclosed are formulae and methods for the simultaneous relief of a variety of unpleasant symptoms of poison ivy on the skin. The compositions of the present invention remove toxic urushiol, relieve itching of the skin from urushiol, and heal the dermatitis caused by urushiol. A preferred embodiment of the invention is a topical dosage form which can be applied as often as desired, may be scrubbed onto the skin, and leaves a soothing effect on the skin after rinsing with warm water.